

David W Schultz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/631479/david-w-schultz-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

1,247
citations

10
h-index

19
g-index

19
ext. papers

1,431
ext. citations

7.2
avg, IF

3.2
L-index

#	Paper	IF	Citations
19	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1.. <i>Genome Medicine</i> , 2022 , 14, 7	14.4	0
18	Urinary neopterin: a novel biomarker of disease progression in amyotrophic lateral sclerosis.. <i>European Journal of Neurology</i> , 2021 ,	6	4
17	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of In Patients With ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021 , 22, 287-299	3.6	10
16	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1991-1999	5.3	2
15	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021 , 1-8	3.6	0
14	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. <i>Cell Reports</i> , 2020 , 33, 108323	10.6	18
13	DSP-01 Barriers to the diagnosis of motor neuron disease - a South Australian study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019 , 20, 289-300	3.6	
12	Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Biomarker Research</i> , 2019 , 7, 3	8	8
11	Factors contributing to delays in the diagnosis of motor neuron disease - A South Australian study. <i>Journal of the Neurological Sciences</i> , 2019 , 407, 116540	3.2	1
10	Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. <i>Lancet Neurology</i> , 2018 , 17, 587-596	24.1	72
9	Urinary p75: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. <i>Neurology</i> , 2017 , 88, 1137-1143	6.5	54
8	Motor neurone disease: progress and challenges. <i>Medical Journal of Australia</i> , 2017 , 206, 357-362	4	17
7	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. <i>BMJ Open</i> , 2016 , 6, e012054	3	25
6	CLIPPERS: Induction and maintenance of remission using hydroxychloroquine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e56	9.1	15
5	The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. <i>PLoS ONE</i> , 2014 , 9, e87398	3.7	44
4	EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration. <i>Stroke</i> , 2011 , 42, 59-64	6.7	84
3	Transient changes on brain magnetic resonance imaging in a patient with sturge-weber syndrome presenting with hemiparesis. <i>Neurologist</i> , 2009 , 15, 351-4	1.6	12

- 2 Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. *Lancet Neurology*, **2008**, 7, 299-309 24.1 873
- 1 Recanalisation and outcome cerebral venous thrombosis. *Journal of Clinical Neuroscience*, **1996**, 3, 133-82.2 8